Melanoma & Skin Cancer

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.

The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

The FDA has granted breakthrough device designation to Merlin CP-GEP, a clinicopathologic gene expression profile test for stratifying risk in early-stage cutaneous melanoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The resubmission of the BLA for RP1 has been accepted for review by the FDA for its use in combination with nivolumab in advanced melanoma.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving biomarker utilization and sequencing strategies in uveal melanoma.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Experts unpack key melanoma data shared during the 2026 ASCO Annual Meeting.

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

Replimune plans to resubmit a BLA for RP1 plus nivolumab after the FDA agreed to prioritize review due to the significant unmet need in advanced melanoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Beth N. McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.